ALX Oncology raises $105m to advance clinical development of ALX148
ALX Oncology, a clinical-stage immuno-oncology company based in California, has raised $105 million in a Series C equity financing round led by Vivo Capital. The ... Read More
Pinpoint Therapeutics secures funds for developing autophagy inhibitors for cancer
Pinpoint Therapeutics, a US biopharma company focused on developing autophagy inhibitors for cancer treatment, has secured $1 million in debt financing led by California-based venture ... Read More
Merck acquires ArQule for $2.7bn to further diversify oncology pipeline
Merck acquisition of ArQule : Merck has completed its previously announced acquisition of ArQule for $20 per share or about $2.7 billion as per the ... Read More
MiraDx to enroll patients for non-tumor based microRNA clinical trial
MicroRNA clinical trial : MiraDx, a Los Angeles-based molecular genetics company, has initiated patient enrollment in collaboration with UCLA for the non-tumor based microRNA biomarker-driven ... Read More
Genetron Health’s semiconductor-based NGS system gets Chinese approval
Genetron Health has been granted approval by China’s National Medical Products Administration (NMPA) for GENETRON S5, its semiconductor-based next-generation sequencing system (NGS system). With the ... Read More
Astellas Pharma acquires US biotech company Xyphos Biosciences
Astellas acquisition of Xyphos : Japanese pharma company Astellas Pharma has acquired US biotech company Xyphos Biosciences in a deal worth up to $665 million ... Read More
Amgen, Allergan file BLA to FDA for Rituxan biosimilar ABP 798
Rituxan biosimilar ABP 798 : US biopharma company Amgen and Irish pharma company Allergan have submitted a Biologics License Application (BLA) to the US Food ... Read More
Astellas, Seattle Genetics bag Padcev FDA approval for advanced urothelial cancer
Padcev FDA approval : Astellas Pharma and Seattle Genetics have bagged accelerated approval from the US Food and Drug Administration (FDA) for Padcev (enfortumab vedotin-ejfv) ... Read More
AbbVie, Scripps Research to collaborate on developing new therapeutics
US biopharma company AbbVie has entered into a collaboration with California-based nonprofit medical research facility Scripps Research with a goal to develop new therapies for ... Read More
Innovent Biologics begins phase 1 trial of IBI315 in solid malignancies
Innovent Biologics and Beijing Hanmi Pharmaceutical, a subsidiary of Hanmi Pharmaceutical, said that the first patient has been dosed in a phase 1 clinical trial ... Read More